ADHD panel calls for added risk information, but no black box

An FDA advisory committee disagreed with an earlier panel's recommendation and said children with attention deficit hyperactivity disorder and their parents need to be advised of risks of drugs for treating their condition, but a black-box warning is unnecessary. The latest panel's chairman said a redesign of drug labels to place important topics at the top could eliminate the need for the most-severe warnings.

View Full Article in:

NYTimes.com · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA